Cargando…
Evaluating Metabolite-Based Biomarkers for Early Diagnosis of Pancreatic Cancer: A Systematic Review
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with five-year survival rates around 10%. The only curative option remains complete surgical resection, but due to the delay in diagnosis, less than 20% of patients are eligible for surgery. Therefore, discovering diagnostic bi...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10384620/ https://www.ncbi.nlm.nih.gov/pubmed/37512579 http://dx.doi.org/10.3390/metabo13070872 |
_version_ | 1785081202062917632 |
---|---|
author | Perazzoli, Gloria García-Valdeavero, Olga M. Peña, Mercedes Prados, Jose Melguizo, Consolación Jiménez-Luna, Cristina |
author_facet | Perazzoli, Gloria García-Valdeavero, Olga M. Peña, Mercedes Prados, Jose Melguizo, Consolación Jiménez-Luna, Cristina |
author_sort | Perazzoli, Gloria |
collection | PubMed |
description | Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with five-year survival rates around 10%. The only curative option remains complete surgical resection, but due to the delay in diagnosis, less than 20% of patients are eligible for surgery. Therefore, discovering diagnostic biomarkers for early detection is crucial for improving clinical outcomes. Metabolomics has become a powerful technology for biomarker discovery, and several metabolomic-based panels have been proposed for PDAC diagnosis, but these advances have not yet been translated into the clinic. Therefore, this review focused on summarizing metabolites identified for the early diagnosis of PDAC in the last five years. Bibliographic searches were performed in the PubMed, Scopus and WOS databases, using the terms “Biomarkers, Tumor”, “Pancreatic Neoplasms”, “Early Diagnosis”, “Metabolomics” and “Lipidome” (January 2018–March 2023), and resulted in the selection of fourteen original studies that compared PDAC patients with subjects with other pancreatic diseases. These investigations showed amino acid and lipid metabolic pathways as the most commonly altered, reflecting their potential for biomarker research. Furthermore, other relevant metabolites such as glucose and lactate were detected in the pancreas tissue and body fluids from PDAC patients. Our results suggest that the use of metabolomics remains a robust approach to improve the early diagnosis of PDAC. However, these studies showed heterogeneity with respect to the metabolomics techniques used and further studies will be needed to validate the clinical utility of these biomarkers. |
format | Online Article Text |
id | pubmed-10384620 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103846202023-07-30 Evaluating Metabolite-Based Biomarkers for Early Diagnosis of Pancreatic Cancer: A Systematic Review Perazzoli, Gloria García-Valdeavero, Olga M. Peña, Mercedes Prados, Jose Melguizo, Consolación Jiménez-Luna, Cristina Metabolites Systematic Review Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with five-year survival rates around 10%. The only curative option remains complete surgical resection, but due to the delay in diagnosis, less than 20% of patients are eligible for surgery. Therefore, discovering diagnostic biomarkers for early detection is crucial for improving clinical outcomes. Metabolomics has become a powerful technology for biomarker discovery, and several metabolomic-based panels have been proposed for PDAC diagnosis, but these advances have not yet been translated into the clinic. Therefore, this review focused on summarizing metabolites identified for the early diagnosis of PDAC in the last five years. Bibliographic searches were performed in the PubMed, Scopus and WOS databases, using the terms “Biomarkers, Tumor”, “Pancreatic Neoplasms”, “Early Diagnosis”, “Metabolomics” and “Lipidome” (January 2018–March 2023), and resulted in the selection of fourteen original studies that compared PDAC patients with subjects with other pancreatic diseases. These investigations showed amino acid and lipid metabolic pathways as the most commonly altered, reflecting their potential for biomarker research. Furthermore, other relevant metabolites such as glucose and lactate were detected in the pancreas tissue and body fluids from PDAC patients. Our results suggest that the use of metabolomics remains a robust approach to improve the early diagnosis of PDAC. However, these studies showed heterogeneity with respect to the metabolomics techniques used and further studies will be needed to validate the clinical utility of these biomarkers. MDPI 2023-07-22 /pmc/articles/PMC10384620/ /pubmed/37512579 http://dx.doi.org/10.3390/metabo13070872 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Systematic Review Perazzoli, Gloria García-Valdeavero, Olga M. Peña, Mercedes Prados, Jose Melguizo, Consolación Jiménez-Luna, Cristina Evaluating Metabolite-Based Biomarkers for Early Diagnosis of Pancreatic Cancer: A Systematic Review |
title | Evaluating Metabolite-Based Biomarkers for Early Diagnosis of Pancreatic Cancer: A Systematic Review |
title_full | Evaluating Metabolite-Based Biomarkers for Early Diagnosis of Pancreatic Cancer: A Systematic Review |
title_fullStr | Evaluating Metabolite-Based Biomarkers for Early Diagnosis of Pancreatic Cancer: A Systematic Review |
title_full_unstemmed | Evaluating Metabolite-Based Biomarkers for Early Diagnosis of Pancreatic Cancer: A Systematic Review |
title_short | Evaluating Metabolite-Based Biomarkers for Early Diagnosis of Pancreatic Cancer: A Systematic Review |
title_sort | evaluating metabolite-based biomarkers for early diagnosis of pancreatic cancer: a systematic review |
topic | Systematic Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10384620/ https://www.ncbi.nlm.nih.gov/pubmed/37512579 http://dx.doi.org/10.3390/metabo13070872 |
work_keys_str_mv | AT perazzoligloria evaluatingmetabolitebasedbiomarkersforearlydiagnosisofpancreaticcancerasystematicreview AT garciavaldeaveroolgam evaluatingmetabolitebasedbiomarkersforearlydiagnosisofpancreaticcancerasystematicreview AT penamercedes evaluatingmetabolitebasedbiomarkersforearlydiagnosisofpancreaticcancerasystematicreview AT pradosjose evaluatingmetabolitebasedbiomarkersforearlydiagnosisofpancreaticcancerasystematicreview AT melguizoconsolacion evaluatingmetabolitebasedbiomarkersforearlydiagnosisofpancreaticcancerasystematicreview AT jimenezlunacristina evaluatingmetabolitebasedbiomarkersforearlydiagnosisofpancreaticcancerasystematicreview |